Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05009927
Recruiting Phase 2

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

NCT05009927 · tracked via the Priya Life Science France tracker
Phase
Phase 2
Started
2022-01-03
Last updated
2023-09-01

Condition(s) studied

Metastatic Gastrointestinal Stromal Tumor (GIST)C-KIT MutationAdvanced Gastrointestinal Stromal Tumor (GIST)

Investigational drug(s) / intervention(s)

Imatinib tablets →

Imatinib tablets: Imatinib interruption

Study summary

This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST.

In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease.

In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients ≥18 years of age; * Histologically documented diagnosis of malignant advanced/metastatic GIST with immunohistochemical documentation of c-kit (CD117) expression either by the primary tumor or metastases; * Eastern Cooperative Oncology Group (ECOG) - Performance status (PS) 0 to 2 evaluated within 7 days prior to the date of inclusion. * Patient must be under imatinib treatment (at 300 or 400mg/day) maintained for 10 years or over with no more than 12 months in total or 3 consecutive months of interruption during the treatment period; * Patient with controlled disease (without any progression under imatinib); * Willingness and ability to comply with scheduled visits, treatment plans , laboratory tests, and other study procedures; * Covered by a medical/health insurance; * Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment. Exclusion Criteria: * Patient concurrently using other approved or investigational antineoplastic agents; * Patient with GIST harboring the mutation D842V in PDGFRA; * Major concurrent disease affecting cardiovascular system, liver, kidneys, haematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures or results; * Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years; * Patient receiving concurrent treatment with warfarin (acceptable alternative: low-molecular weight heparin) or any prohibited concomitant and/or concurrent medications * Patient has a known diagnosis of human immunodeficiency virus (HIV) infection; * Major surgery within 2 weeks prior to study entry. * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. * Pregnant or breastfeeding woman * Patient requiring tutorship or curatorship or patient deprivied of liberty.

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
CHU Besançon Besançon France Recruiting
Institut Bergonié Bordeaux France Recruiting
CHU Dupuytren Limoges France Recruiting
Centre Léon Bérard Lyon France Recruiting
Institut Paoli Calmettes Marseille France Not Yet Recruiting
Institut Curie Paris France Not Yet Recruiting
CHU de Reims Reims France Recruiting
Centre Eugène Marquis Rennes France Not Yet Recruiting
Institut de Cancérologie de l'Ouest - Site Réné Gauducheau Saint-Herblain France Not Yet Recruiting
Institut de Cancérologie Lucien NEUWIRTH Saint-Paul-en-Jarez France Not Yet Recruiting
Institut Claudius Regaud Toulouse France Not Yet Recruiting
Institut de Cancérologie de Lorraine Vandœuvre-lès-Nancy France Not Yet Recruiting
Institut Goustave Roussy Villejuif France Recruiting

More Centre Leon Berard trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05009927 on ClinicalTrials.gov ↗ ← All trials in France